Hui-Yu Bai Selected Research

Type 2 Angiotensin Receptor

1/2019	AT2 receptor stimulation inhibits phosphate-induced vascular calcification.
10/2018	Attenuation of stroke damage by angiotensin II type 2 receptor stimulation via peroxisome proliferator-activated receptor-gamma activation.
1/2018	Beneficial Effect of Mas Receptor Deficiency on Vascular Cognitive Impairment in the Presence of Angiotensin II Type 2 Receptor.
1/2016	Synergistic Inhibitory Effect of Rosuvastatin and Angiotensin II Type 2 Receptor Agonist on Vascular Remodeling.
12/2015	Angiotensin II type 2 receptor signaling affects dopamine levels in the brain and prevents binge eating disorder.
4/2015	Direct angiotensin II type 2 receptor stimulation by compound 21 prevents vascular dementia.
8/2014	Direct stimulation of angiotensin II type 2 receptor initiated after stroke ameliorates ischemic brain damage.
3/2014	Possible role of angiotensin-converting enzyme 2 and activation of angiotensin II type 2 receptor by angiotensin-(1-7) in improvement of vascular remodeling by angiotensin II type 1 receptor blockade.
2/2014	Possible synergistic effect of direct angiotensin II type 2 receptor stimulation by compound 21 with memantine on prevention of cognitive decline in type 2 diabetic mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hui-Yu Bai Research Topics

Disease

6	Cognitive Dysfunction 04/2020 - 02/2014
5	Vascular System Injuries 01/2016 - 03/2014
4	Vascular Remodeling 01/2016 - 03/2014
3	Stroke (Strokes) 10/2018 - 08/2014
2	Dementia (Dementias) 04/2020 - 10/2018
2	Neointima 01/2016 - 01/2016
2	Body Weight (Weight, Body) 12/2015 - 07/2014
1	Hyperglycemia 10/2022
1	Transient Ischemic Attack 04/2020
1	Vascular Calcification 01/2019
1	Brain Injuries (Brain Injury) 10/2018
1	Neurologic Manifestations (Neurological Manifestations) 10/2018
1	Carotid Stenosis (Carotid Artery Stenosis) 01/2018
1	Obesity 01/2016
1	Fetal Growth Retardation (Intrauterine Growth Retardation) 01/2016
1	Feeding and Eating Disorders (Eating Disorder) 12/2015
1	Binge-Eating Disorder (Binge Eating Disorder) 12/2015
1	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 04/2015
1	Brain Edema (Cerebral Edema) 08/2014
1	Brain Ischemia (Cerebral Ischemia) 06/2013
1	Central Nervous System Diseases (CNS Diseases) 05/2013

Drug/Important Bio-Agent (IBA)

9	Type 2 Angiotensin ReceptorIBA 01/2019 - 02/2014
7	compound 21IBA 10/2022 - 02/2014
5	Angiotensin IIIBA 10/2022 - 01/2016
4	Polyethylene (Polythene)IBA 01/2016 - 03/2014
3	Superoxides (Superoxide)IBA 04/2020 - 01/2016
2	NADP (NADPH)IBA 04/2020 - 10/2018
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2019 - 10/2018
2	EnzymesIBA 01/2018 - 01/2016
2	Angiotensin-Converting Enzyme 2IBA 01/2018 - 03/2014
2	AngiotensinsIBA 01/2018 - 01/2016
2	Messenger RNA (mRNA)IBA 01/2016 - 07/2014
2	Proliferating Cell Nuclear Antigen (PCNA)IBA 01/2016 - 01/2016
2	CytokinesIBA 01/2016 - 01/2015
2	Proteins (Proteins, Gene)FDA Link 01/2016 - 01/2016
2	azilsartanIBA 04/2015 - 07/2014
1	NADPH Oxidases (NAD(P)H oxidase)IBA 04/2020
1	neutrophil cytosol factor 40KIBA 04/2020
1	Receptor for Advanced Glycation End ProductsIBA 04/2020
1	Amyloid (Amyloid Fibrils)IBA 04/2020
1	InterleukinsIBA 04/2020
1	Monocyte Chemoattractant ProteinsIBA 04/2020
1	Adenine FDA LinkGeneric 01/2019
1	Phosphates (Orthophosphate)IBA 01/2019
1	Interferon Regulatory FactorsIBA 10/2018
1	Interferon Regulatory Factor-1 (Interferon Regulatory Factor 1)IBA 10/2018
1	PPAR gammaIBA 10/2018
1	2-chloro-5-nitrobenzanilideIBA 10/2018
1	Superoxide DismutaseIBA 10/2018
1	salicylhydroxamic acid (SHAM)IBA 01/2018
1	NAD (NADH)IBA 01/2016
1	LipidsIBA 01/2016
1	Rosuvastatin Calcium (Crestor)FDA Link 01/2016
1	Dopamine (Intropin)FDA LinkGeneric 12/2015
1	Angiotensin Receptor AntagonistsIBA 09/2015
1	sacubitril and valsartan sodium hydrate drug combinationIBA 09/2015
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2015
1	Interleukin-6 (Interleukin 6)IBA 01/2015
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2015
1	angiotensin I (1-7)IBA 03/2014
1	Type 1 Angiotensin ReceptorIBA 03/2014
1	Memantine (Namenda)FDA Link 02/2014
1	Purinergic P2X7 ReceptorsIBA 06/2013
1	Adenosine Triphosphate (ATP)IBA 05/2013

Therapy/Procedure

1	Protein-Restricted Diet (Diet, Protein Restricted) 01/2016